Intellia reports positive results for its CRISPR-based treatment

Intellia Therapeutics mentioned Sunday that the primary 10 sufferers to obtain a CRISPR-based therapy for hereditary angioedema, a genetic illness, noticed their swelling assaults — the situation’s hallmark symptom — nearly eradicated for a mean of 20 months and counting.

The assaults had been decreased by a mean of 98%. One affected person has remained attack-free for 26 months. Two sufferers who suffered significantly frequent assaults, experiencing 14 and 16.8 monthly, respectively, have now gone greater than 20 months since their final assault.

No affected person has had an assault within the final 11 months of follow-up, in line with the information introduced on the European Academy of Allergy and Scientific Immunology Congress. All unwanted effects had been both grade 1 or 2 on a 5-grade scale.